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Serotonin Transporter Inhibition Prevents and Reverses
Monocrotaline-Induced Pulmonary Hypertension in Rats
Christophe Guignabert, PhD; Bernadette Raffestin, MD, PhD;
Rima Benferhat, MS; William Raoul, PhD; Patricia Zadigue; Dominique Rideau; Michel Hamon, PhD;
Serge Adnot, MD, PhD; Saadia Eddahibi, PhD
Background—Progression of pulmonary hypertension (PH) is associated with increased lung expression of the serotonin
transporter (5-HTT), which leads to hyperplasia of the pulmonary artery smooth muscle cells (PA-SMCs). Given the
postulated causal relation between 5-HTT overexpression and PH, we herein investigated whether the highly selective
5-HTT inhibitor fluoxetine prevented and/or reversed PH induced by monocrotaline (MCT) in rats. Selective 5-HT1B/1D,
5-HT2A, and 5-HT2B receptor antagonists were used for comparative testing.
Methods and Results—MCT injection (60 mg/kg SC) was followed by an early peak in lung 5-HTT expression on day
1, which preceded the onset of PH. Established PH on day 15 was associated with a sustained 5-HTT increase.
Continued fluoxetine treatment completely prevented PA-SMC proliferation and PH development and also suppressed
the late 5-HTT increase, without affecting the early peak. The 5-HT receptor antagonists did not affect PH. Fluoxetine
(10 mg · kg1 · d1 PO) started 3 weeks after MCT injection completely reversed established PH, normalizing PA
pressure and structure. MCT-induced PH was also associated with increased expression of various cytokines, but only
interleukin-1 and monocyte chemotactic protein-1 increased at the early phase and stimulated 5-HTT expression by
cultured PA-SMCs.
Conclusion—Upregulation of lung 5-HTT induced by MCT appears necessary to initiate the development of pulmonary
vascular remodeling, whereas a sustained increase in 5-HTT expression may underlie both the progression and the
maintenance of MCT-induced PH. Complete reversal of established PH by fluoxetine provides a rationale for new
therapeutic strategies in human PH. (Circulation. 2005;111:2812-2819.)
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Pulmonary hypertension (PH) occurs either as a compli-cation of various disease states or as a primary disease for
which no underlying cause can be found. Smooth muscle
hyperplasia is a hallmark pathological feature of all forms of
PH and leads to structural remodeling and occlusion of the
pulmonary vessels.1 We recently reported that serotonin
(5-hydroxytryptamine, 5-HT) and its transporter (5-HTT)
play a central role in the pathogenesis of pulmonary artery
smooth muscle cell (PA-SMC) proliferation, not only in
experimental hypoxic PH but also in human PH, whether
primary or secondary to pulmonary or systemic diseases.2,3
The increased 5-HTT expression that governs PA-SMC
proliferation in patients with PH is at least partly related to
polymorphism of the 5-HTT promoter gene.3,4 This implies
that the 5-HT pathway involving 5-HTT contributes to the
pathogenesis of various forms of human PH and/or is an
important modifier of the PH phenotype.5 Recent studies
showing that mice overexpressing 5-HTT develop PH in the
absence of other stimuli also support the concept that 5-HTT
upregulation precedes the development of pulmonary vascu-
lar remodeling.6
Whether 5-HTT may be a molecular target for the treat-
ment of PH remains to be established. We previously found
that hypoxia-induced PH was strikingly attenuated in mice
deficient in 5-HTT and in wild-type mice treated with 5-HTT
inhibitors.7 However, some pulmonary vascular remodeling
was still observed after genetic or pharmacological inactiva-
tion of 5-HTT, and hypoxic pulmonary vasoconstriction was
potentiated, possibly because of a stimulatory effect of 5-HT
on at least some 5-HT receptors. In some studies, but not all,
treatment with drugs antagonizing 5-HT1B and 5-HT2B recep-
tors seemed to also attenuate the development of hypoxic
PH.8,9
The potential effectiveness of drugs interfering with 5-HT,
however, has not been tested in severe experimental PH such
as that induced by monocrotaline (MCT) in rats. MCT is a
pyrrolizidine alkaloid toxin that produces endothelial injury
followed by progressive development of severe and irrevers-
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ible PH. We chose this experimental inflammatory model of
PH to assess the role of the 5-HTT versus 5-HT receptors
because MCT-induced PH results primarily from marked
alterations in PA structure, including medial hypertrophy and
intimal fibromuscular hyperplasia, similar to those observed
in some forms of human PH.10 We therefore investigated
whether the selective 5-HTT inhibitor fluoxetine or specific
antagonists of 5-HT1B/1D, 5-HT2A, and 5-HT2B receptors pre-
vented or reversed established MCT-induced PH in rats.
Because inflammation contributes to MCT-induced PH and
to various forms of human PH, we also measured the
expression of inflammatory cytokines in parallel with 5-HTT
during the course of MCT-induced PH. Finally, whether
cytokines affected 5-HTT expression was also investigated in
isolated PA-SMCs.
Methods
Animal Models and Experimental Design
All experiments were performed in adult male Wistar rats (200 to
250 g) according to institutional guidelines that comply with national
and international regulations.
In the first part of the study, PH development and pulmonary
expression of cytokines and 5-HTT were examined in rats at various
times after a single injection of MCT (60 mg/kg SC, Sigma). Then,
to assess the potential preventive effect of 5-HTT inhibition or 5-HT
receptor blockade on MCT-induced PH, we assigned rats at random
to 1 of 6 groups (8 to 10 animals in each group): 2 groups received
fluoxetine at 2 or 10 mg · kg1 · d1; 1 group each received the
selective 5-HT1B/1D receptor antagonist GR127935 (2 mg · kg1 · d1),
the 5-HT2A receptor antagonist ketanserin (2 mg · kg1 · d1), or the
5-HT2B receptor antagonist RS127445 (2 mg · kg1 · d1); and 1
group received vehicle only. All treatments were given once a day by
gavage for 3 weeks after a single MCT injection (60 mg/kg SC).
Finally, to assess the potential curative effects of 5-HTT inhibition,
rats given MCT (60 mg/kg SC) were left untreated for 21 days and
then randomly divided into 2 groups, 1 treated with fluoxetine (10
mg · kg1 · d1) and the other with vehicle, from day 21 to day 42.
Assessment of PH
Three or 6 weeks after MCT administration, rats were anesthetized
with ketamine (60 mg/kg IM) and xylazine (3 mg/kg IM). A
polyvinyl catheter was introduced into the right jugular vein and
pushed through the right ventricle into the PA. Another polyethylene
catheter was inserted into the right carotid artery. After measurement
of PA (PAP) and systemic arterial (SAP) pressures, the thorax was
opened and the left lung immediately removed and frozen in LN2 for
measurement of cytokines and 5-HTT expression. The heart was
dissected and weighed for calculation of the right ventricular
hypertrophy index (ratio of right ventricular free wall weight divided
by the sum of the septum plus left ventricular free wall weight
[RV/{LVS}]). The right lung was fixed in the distended state with
formalin buffer. After paraffin embedding, 5-m-thick lung sections
were stained with hematoxylin-phloxine-safranin. In each rat, 40 to
60 intra-acinar arteries were analyzed and categorized as muscular-
ized (fully or partially) or nonmuscularized to assess the degree of
muscularization. In addition, medial wall thickness of fully muscu-
larized intra-acinar arteries was calculated and expressed as follows:
index (%)(external diameterinternal diameter)/external diame-
ter100. Cell proliferation and apoptosis were also assessed in the
walls of distal pulmonary vessels from rats treated with vehicle or
fluoxetine on day 21 or 42 after MCT administration.
Real-Time Quantitative RT-PCR for Measurement
of Lung 5-HTT, Interleukin-1, Monocyte
Chemotactic Protein-1, and Interleukin-6 mRNA
RNA extraction was performed with Trizol reagent (Gibco BRL).
The concentration and quality of RNA were determined by electro-
phoresis on agarose gel and spectrophotometry. Then, reverse
transcription was performed with random hexamer primers and
reverse transcriptase (RT, Biotech Ltd). Primers for polymerase
chain reaction (PCR) were designed with Primer Express Software
(Applied Biosystems). To avoid inappropriate amplification of
residual genomic DNA, intron-spanning primers were selected and
internal control 18S rRNA primers provided. For each sample, the
amplification reaction was performed in duplicate with SyberGreen
mix and specific primers. Signal detection and analysis of results
were performed with ABI-Prism 7000 sequence detection software
(Applied Biosystems). The relative expression level of the genes of
interest was computed relative to the mRNA expression level of the
internal standard, r18S, by the following formula: relative
mRNA1⁄2(Ct
gene of interest
Ctr18S).
Lung 5-HTT Immunoblotting
and Immunolocalization
Detection and quantification of 5-HTT protein in lung tissue were
achieved by Western blotting. In brief, lung samples were homoge-
nized in ice-cold phosphate-buffered saline (PBS). Total protein (150
g) from each sample was separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and then transferred to a nitro-
cellulose membrane. After incubation in a blocking solution for 1
hour, the membranes were incubated with a 5-HTT antibody as
previously described.7 Densitometric quantification was normalized
for -actin level in each sample. Localization of 5-HTT was
performed by immunostaining of lung tissue sections as previously
described.7
Evaluation of In Situ PA-SMC Death
and Proliferation
To assess PA-SMC proliferation in rats treated with MCT alone or
with fluoxetine, the proliferating cell nuclear antigen (PCNA) was
evaluated. Tissue sections were deparaffinized in xylene and then
treated with a graded series of alcohol washes, rehydrated in PBS
(pH 7.5), and incubated with target retrieval solution (Dako) in a
water bath at 90°C for 20 minutes. Endogenous peroxidase activity
was blocked with H2O2 in PBS (3%, vol/vol) for 5 minutes. Slides
were then washed in PBS, incubated for 30 minutes in a protein-
blocking solution, and incubated for 30 minutes with anti-PCNA
mouse monoclonal antibody (PC-10, 1:200, Dako). Antibodies were
washed off, and the slides were processed with the alkaline phos-
phatase LSAB system horseradish peroxidase detection kit (Dako).
Brown color was generated with a diaminobenzidine substrate, and
nuclei were counterstained with hematoxylin.
Detection of cells undergoing apoptosis was achieved with the
ApopTag Red in situ apoptosis detection kit (Qbiogene), as specified by
the manufacturer. At the end of the procedure, the samples were
observed by fluorescence microscopy after Hoechst staining (Sigma).
Effects of Cytokines on 5-HTT Expression by
Isolated PA-SMCs
SMCs from control rat PAs were cultured and characterized as
previously described.2 To examine the effects of cytokines on 5-HTT
expression, the cells were grown to confluence and the medium was
removed. The cells were then exposed to interleukin (IL)-1, IL-6,
or monocyte chemotactic protein (MCP)-1 (10 ng/mL) in serum-free
medium for 4 or 24 hours. Then the samples were used for real-time
quantitative RT-PCR or Western blotting.
Statistical Analyses
The data are expressed as meanSEM. A nonparametric Mann-
Whitney test was used for comparisons between 2 groups. Compar-
isons of data at various times after MCT injection or of various
treatment groups were performed with a nonparametric Kruskal-
Wallis test followed by Dunn test when significant. The mortality
rates between vehicle- and fluoxetine-treated animals were compared
by 2 tests. The effect of fluoxetine on 5-HTT and cytokine
expression in the lung at various times after MCT injection was
evaluated by 2-way ANOVA, testing for treatment and time effects.
When a time-by-treatment interaction was found, comparisons be-
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tween vehicle and active treatment were performed with a nonpara-
metric Mann-Whitney test.
Results
Development of PH and Time-Dependent
Increase in Lung 5-HTT Expression After
MCT Administration
Administration of MCT was followed by delayed increases in
the ratio of RV/(LVS), reflecting right ventricular hypertrophy
(Figure 1A, left) and in the percentage of partially or fully
muscularized distal vessels (reflecting pulmonary vessel remod-
eling, Figure 1A, right). In both cases, the increase became
significant on day 15 compared with control rats and continued
from day 15 to day 21. Lung levels of 5-HTT mRNA and 5-HTT
protein increased early after MCT injection (Figure 1B), reach-
ing a peak within the first 24 hours, decreasing slightly for the
following 10 days, and then increasing again until the last day of
the study (day 21). As shown in Figure 1B, 5-HTT expression
remained significantly enhanced from day 1 to day 21 after
MCT administration.
Effects of Treatment With Fluoxetine or 5-HT
Receptor Antagonists on Development of
MCT-Induced PH
In rats treated with vehicle after MCT administration and studied
on day 21, severe PH developed, with marked increases in PAP,
RV/(LVS) (Table), and PA muscularization (Figure 2A and
2B) compared with control rats injected with saline instead of
MCT. Long-term treatment with the selective 5-HT1B/1D receptor
antagonist GR127935 (2 mg kg1 d1), the 5-HT2A receptor antag-
onist ketanserin (2 mg kg1 d1), or the 5-HT2B receptor
antagonist RS127445 (2 mg kg1 d1) for 21 days after MCT
injection did not affect these parameters. In contrast, with
fluoxetine, the development of PH was markedly attenuated
with the lowest dose (2 mg/kg) and completely abolished
with the highest dose (10 mg/kg). PAP, RV/(LVS), and
muscularization of distal PAs were significantly lower in
MCT-treated rats given fluoxetine than in those given vehicle; in
MCT-treated rats given the high fluoxetine dose (10 mg/kg),
these values were similar to those determined in control rats
treated with vehicle instead of MCT. 5-HTT immunostaining of
lung sections demonstrated a marked increase in 5-HTT immu-
noreactivity, located mainly in the media of PAs and correlated
with media thickening (Figure 3).
During the 21-day follow-up, no deaths occurred in the
MCT group. To examine the effect of fluoxetine treatment on
survival, we followed up 2 groups of MCT-treated rats for 42
days; 1 group had received vehicle and the other, fluoxetine
(10 mg kg1 d1), from day 1 to day 21. Among vehicle-
treated rats, 40% died between days 30 and 35 after MCT,
whereas none of the fluoxetine-treated rats died during the
42-day follow-up (P0.01).
Reversal of MCT-Induced PH With Fluoxetine
In rats treated with fluoxetine from day 21 to day 42 (10
mg kg1 d1) after MCT injection, PAP, RV/(LVS), PA
Figure 1. A, Development of right ven-
tricular hypertrophy as assessed by
weight ratio RV/(LVS) (left) and muscu-
larization of distal pulmonary vessels
estimated by percentage of muscularized
intra-acinar vessels (right). B, 5-HTT
mRNA expression in lung tissue (left)
performed by real-time quantitative
RT-PCR, and protein levels (right)
assessed by densitometric quantification
of 5-HTT immunoblotting normalized
against -actin level. Each point is
meanSE of at least 5 determinations at
various times after MCT administration
(mean SE, n5 at each time). *P0.05,
†P0.01 compared with values obtained
in control, untreated rats (day 0).
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muscularization, SAP, and heart rate on day 42 did not differ
from those values in control rats given vehicle instead of
MCT (Figure 4). In contrast, in vehicle-treated rats, PH
worsened between days 21 and 42 (values reported in the
Table and Figure 4), and PA wall thickness increased mark-
edly, as illustrated in Figure 5.
Effect of Fluoxetine Treatment on PA-SMC
Proliferation and Apoptosis
In MCT rats treated with vehicle, PCNA labeling showed
proliferation of SMCs in distal PA walls, which was more
marked at 42 than at 21 days. The number of PCNA-positive
cells was markedly lower in PA walls from rats treated with
Body Weight (BW), Heart Weight, and Hemodynamic Data in Rats at Day 21 After MCT Administration
MCT
Controls
(n6)
Vehicle
(n8)
GR127
(n6)
RS144
(n8)
Ket
(n5)
Fluox,
2 mg  kg1  d1
(n5)
Fluox,
10 mg  kg1  d1
(n5)
BW, g 3619 3047* 3066* 3215* 3118* 3159* 3255*
PAP, mm Hg 19.11.2 30.73.6* 28.61.8* 27.92.3* 29.21.9* 20.31.4† 18.50.9†
SAP, mm Hg 1086 955 1047 945 9910 10112 1025
Heart rate, bpm 30821 34415 35326 33327 32414 29630 30023
Hematocrit, % 472 444 483 464 435 463 454
RV, mg 1556 2468* 2376* 2547* 2569* 1814*† 1593‡
LVS, mg 55114 5399 52411 5468 52910 52212 53613
RV/(LVS) 0.280.01 0.470.03* 0.480.04* 0.460.03* 0.500.02* 0.350.02*† 0.300.02‡
Ket indicates ketanserin; fluox, fluoxetine. All values are meanSEM.
*P0.01 compared with corresponding values in control rats (controls) given saline instead of MCT.
†P0.01, ‡P0.001 compared with MCT-treated rats given vehicle.
Figure 2. A, Percentage of nonmuscular-
ized (NM), partially muscularized (PM), or
fully muscularized (M) distal vessels.
Total of 40 to 60 intra-acinar vessels was
analyzed in each lung from rats injected
with MCT and treated daily with
GR127935 (GR; 2 mg kg1 d1, n10),
RS127445 (RS; 2 mg kg1 d1, n10),
ketanserin (Ket; 2 mg kg1 d1, n8), flu-
oxetine (Fluox; 2 or 10 mg kg1 d1,
n10 for each dose), or vehicle (Ve,
n10) for next 21 days. Compared with
control rats, MCT caused increase in
muscularization (P0.001). Degree of
muscularization in MCT rats was lower in
fluoxetine-treated (2 and 10 mg kg1 d1)
groups than in vehicle-treated groups
(P0.05 and P0.01, respectively).
There was no difference between
GR127935, RS127445, ketanserin, and
vehicle-treated rats. B, Pulmonary vascu-
lar remodeling illustrated by representa-
tive photomicrographs of pulmonary ves-
sels from each group of rats.
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fluoxetine on both days 21 and 42. In contrast to the large
number of PCNA-positive cells, the number of apoptotic cells
detected by terminal dUTP nick end-labeling (TUNEL) was
very low in PA walls from MCT animals treated with vehicle
or fluoxetine on both days 21 and 42 (Figure 6).
Lung Expression of Cytokines and 5-HTT
After MCT Treatment in Rats Given Vehicle
or Fluoxetine
Pulmonary expression of the cytokines IL-1, IL-6, and
MCP-1, previously shown to be involved in the inflammatory
response to MCT,11–13 was measured at various times after
MCT injection. The results showed early peaks in IL-1  and
MCP-1 mRNA levels within the first 24 hours, followed by a
transient decrease on day 5, and then by a gradual increase
from day 5 to day 21 (Figure 7). In contrast, lung IL-6 mRNA
remained undetectable until day 5 but then increased sharply
to reach a plateau from day 10 to day 21 (Figure 7).
Long-term treatment with fluoxetine (10 mg/kg) abolished
the late increases in IL-6, MCP-1, and IL-1  mRNA but did
not affect the early peaks in IL-1 and MCP-1 mRNA levels
(Figure 7). Similarly, treatment with fluoxetine suppressed
the late increase in 5-HTT protein on day 21, from 1.260.05
to 0.500.03 U (5-HTT/-actin density; P0.01) but had no
influence on the early peak on day 1.
Effect of Inflammatory Cytokines on 5-HTT
Expression in Isolated Rat PA-SMCs
The potential effects of various inflammatory cytokines on
5-HTT expression were examined in cultured PA-SMCs from
control rats. Incubation of PA-SMCs with IL-1 or MCP-1
for 4 or 24 hours induced an increase in 5-HTT mRNA or
protein levels, respectively, compared with cells incubated
with vehicle (P0.05) (Figure 8). However, incubation of
PA-SMCs with IL-6 did not change the levels of 5-HTT
mRNA or protein.
Discussion
The main finding from the present study is that treatment with
5-HTT inhibitors not only prevents but also completely
reverses PH induced by MCT in rats. In this model of severe
PH, the highest dose of the 5-HTT inhibitor fluoxetine
completely prevented death and PH development, as shown
by the hemodynamic values similar to those in control
animals and by the absence of both right ventricular hyper-
trophy and pulmonary vessel remodeling. Moreover, fluox-
etine treatment resulted in complete reversal of established
PH. Whereas PAP, right ventricular hypertrophy, distal PA-
SMC proliferation, and wall thickness continued to increase
from day 21 to day 42 in rats given vehicle, these values and
vessel muscularization returned to normal in rats given
fluoxetine.
MCT causes early endothelial injury of PAs and an
inflammatory response, which precede the onset of PA-SMC
proliferation and the development of PH.10 In the present
study, we showed an early increase in 5-HTT protein expres-
sion in lung tissue at a time when PA-SMC proliferation was
not yet detectable. Levels of 5-HTT mRNA and protein
peaked 12 to 24 hours after MCT injection and then de-
creased slightly but remained elevated thereafter. In rats that
Figure 4. PAP, right ventricular hypertro-
phy as assessed by weight ratio
RV/(LVS), and percentage of nonmus-
cularized (NM), partially muscularized
(PM), or fully muscularized (M) vessels in
rats on day 42 after saline (controls) or
MCT administration combined with fluox-
etine (Fluox) or vehicle (Ve) treatment
from day 21 to day 42 (n10 in each
group). *P0.01 compared with values in
control rats.
Figure 3. 5-HTT immunostaining in PAs
from control rats (controls) and from rats
injected with MCT and treated daily with
GR127935 (MCTGR), RS127445
(MCTRS), ketanserin (MCTKet), fluox-
etine at 2 or 10 mg kg1 d1
(MCTFluox2 and MCTFluox 10), or
vehicle (MCTVe). 5-HTT–like immunore-
activity was mainly confined to SMCs of
PAs in all groups. Scale bar100 m.
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were given fluoxetine and did not develop PH, the early
increase in lung 5-HTT expression was unaffected, whereas
the late increase in 5-HTT measured on day 21 was abolished.
The most plausible interpretation of these data is that reduc-
tion of pulmonary vascular remodeling, and thereby of the
number of SMCs, explained the large reduction in 5-HTT
expression observed after fluoxetine treatment. These data
constitute good evidence that early upregulation of lung
5-HTT in response to MCT is necessary to initiate PA-SMC
proliferation and the subsequent development of PH. All
fluoxetine-treated rats were still alive 42 days after MCT
administration, whereas 40% of the vehicle-treated ani-
mals died between days 30 and 35. The fact that in
vehicle-treated rats death occurred after establishment of
PH highly suggests that the beneficial effect of fluoxetine
on survival was related to prevention of PH. Moreover, the
observation that fluoxetine not only prevented but also
reversed established PH is evidence that a sustained
increase in 5-HTT expression is necessary for both the
progression and maintenance of MCT-induced PH. In
vehicle-treated rats, medial thickness of distal PAs in-
creased markedly between days 21 and 42, and vascular
cell proliferation as assessed by PCNA labeling was
observed on day 21 but was even more marked on day 42.
In contrast, treatment with fluoxetine from day 21 to 42
was associated with a reduction in PCNA labeling on day
42, together with complete reversal of PH and distal vessel
remodeling. Because the number of TUNEL-positive
SMCs was very small in both conditions, it is likely that
fluoxetine reversed PH by inhibiting the sustained marked
proliferation of cells that was needed for the maintenance
and late aggravation of PH as a consequence of 5-HTT
overexpression.
Interestingly, marked PH prevention was observed not only
with the highest daily dose, 10 mg/kg PO of fluoxetine, but
also with 2 mg/kg PO, a dose within the therapeutic range (20
to 120 mg daily) used in humans with depression and other
psychopathological conditions.14 Direct assessment of 5-HTT
blockade and its biochemical/behavioral consequences in
vivo in rodents showed that maximal effects were achieved
with the systemic administration of 10 mg/kg fluoxetine,
although significant 5-HT uptake inhibition was already
obtained with 1 to 3 mg/kg.15,16 Furthermore, it has been
demonstrated that the effects of low-dose fluoxetine (on brain
neurotransmission) are significantly larger under subchronic
versus acute treatment conditions,17,18 probably because of
the long half-lives (at least 2 days) of the drug and its active
metabolite norfluoxetine.14 All of these features are in accor-
dance with our observations that fluoxetine at only 2 mg/kg
PO daily for 3 weeks effectively prevented MCT-induced PH
as a result of its established ability to inhibit 5-HTT.
In contrast to fluoxetine, the 5-HT2A receptor antagonist
ketanserin, the 5-HT2B receptor antagonist RS127445, and the
5-HT1B/1D receptor antagonist GR127935 failed to prevent
MCT-induced PH. These results are in accordance with
previous data showing that the mitogenic effect of 5-HT on
SMCs is not altered by these receptor antagonists but is
abolished by the 5-HTT inhibitor fluoxetine.2,4,19,20 The fact
that MCT-induced PH is due chiefly to pulmonary vascular
Figure 5. Pulmonary vascular remodeling as assessed by PA
wall thickness index 21 and 42 days after MCT administration.
Treatment with fluoxetine from day 21 to day 42 completely
reversed medial wall hypertrophy of PAs. Control rats were
studied 42 days after saline. Each value is meanSE of 10 inde-
pendent determinations. *P0.01 compared with values in con-
trol, saline-treated rats. †P0.01 compared with values in MCT-
treated rats given vehicle.
Figure 6. Rat PA-SMC proliferation (PCNA,
A–D) and apoptosis (E–H) on days 21 and
42 after MCT injection. Medial hypertrophy
was associated with increased number of
proliferating vascular cells, shown by immu-
nohistochemistry for PCNA; dark nuclei are
PCNA-positive cells, which were more
numerous after 42 than after 21 days (A and
C). Prevention and regression of medial hy-
pertrophy induced by fluoxetine (10
mg kg1 d1) was attributed to inhibition of
PA-SMC proliferation (B and D). In contrast,
number of apoptotic cells (in situ TUNEL
assays) was very lower in PA walls from
MCT animals treated with vehicle (E and C)
or fluoxetine (F and H).
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remodeling probably explains the efficacy of fluoxetine in
this model. Previous findings that rats treated with selective
5-HT1D/1B or 5-HT2A receptor antagonists8,21 and mice lacking
the 5-HT1B receptor gene8 develop less severe chronic exper-
imental PH and a milder degree of vascular remodeling than
relevant paired controls probably reflect the effects of these
drugs on 5-HT–mediated pulmonary vasoconstriction or on
5-HT–independent mechanisms. Recent studies have also
emphasized the contribution of 5-HT2B receptors to hypoxia-
induced PH.9 In the present work, the antagonists used in
those previous studies had no influence on MCT-induced PH.
These results are somewhat discordant with previous findings
showing attenuation of MCT-induced PH with 5-HT2A antag-
onists.21 However, in those studies, none of the antagonists
was capable of reversing advanced disease or of completely
inhibiting MCT-induced PH. Taken together with our previ-
ous findings that 5-HTT inhibitors, but not 5-HT1D/1B or
5-HT2A receptor antagonists, affect hypoxia-induced PH,
these results provide evidence for a predominant role of
5-HTT over 5-HT receptors in both hypoxia- and MCT-
induced PH.
The hypothesis that inflammatory cytokines are involved
in the process of pulmonary vascular remodeling has long
been suggested on the basis of experimental and human
studies.11 The present results showing early increases in
IL-1 and MCP-1 expression after MCT administration are
consistent with the concept that inflammation plays a key role
in initiating PH in this model.10 Indeed, a similar early
increase in lung IL-1 mRNA has been reported, as well as a
reduction in MCT-induced PH, in rats treated with an
anti–MCP-1 antibody or an IL-1 receptor antagonist.12,13 In
our studies, high values of IL-6 mRNA were detected only
from day 10 onward, concomitant with second elevations in
IL-1 and MCP-1 associated with the development of PH.
Because treatment with fluoxetine completely abolished the
late increases in IL-1, MCP-1, and IL-6 mRNA on day 21,
it is likely that these late changes occurred as a consequence
rather than as a cause of PH. Treatment with fluoxetine,
however, did not affect the early increase in IL-1 that
coincided with the rise in 5-HTT. Treatment of isolated
PA-SMCs with IL-1 or MCP-1 induced a nearly 2-fold
increase in 5-HTT mRNA levels, whereas IL-6 had no effect,
suggesting that the early rises in IL-1 and MCP-1 in
response to MCT may have contributed to the increase in
5-HTT protein and to the subsequent PA-SMC prolifera-
tion. Such an increase in 5-HTT mRNA in response to
IL-1 has previously been found in human choriocarci-
noma cell lines.22,23 Therefore, these in vitro and in vivo
data provide good evidence for a relation between inflam-
matory mediators and the 5-HT pathway in the pathogen-
esis of MCT-induced PH.
Whether inflammation contributes to the pathogenesis of
human PH via stimulation of 5-HTT expression and whether
treatment with 5-HTT inhibitors holds therapeutic potential in
Figure 7. A, Time course of IL-1, IL-6,
and MCP-1 mRNA levels in lungs from
rats after MCT administration (n5 in
each group). *P0.05 and †P0.01
compared with values in control,
untreated rats (day 0). B, IL-1, IL-6, and
MCP-1 mRNAs in lung tissue from rats
treated with fluoxetine (Fluox, 10
mg kg1 d1) or vehicle (Ve) on days 1
and 21 after MCT administration.
*P0.01 compared with corresponding
values in MCT-treated rats given vehicle
and studied under similar conditions.
Figure 8.mRNA and protein levels of 5-HTT
in cultured PA-SMCs after stimulation by
IL-1, IL-6, and MCP-1 (10 ng/mL) or vehi-
cle. 5-HTT mRNA expression was performed
by real-time quantitative RT-PCR, and pro-
tein levels were assessed by densitometric
quantification of 5-HTT immunoblotting nor-
malized for -actin level. Results are
expressed as percentage of levels in
PA-SMCs incubated with vehicle (controls).
Values are meanSEM of 5 independent
experiments. *P0.05 compared with values
obtained in control PA-SMCs.
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the various forms of human PH are extremely important
questions. Many patients with PH exhibit clear-cut signs of
inflammation, including elevated circulating and lung levels
of proinflammatory cytokines such as IL-1, IL-6, platelet-
derived growth factor, macrophage inflammatory protein-1,
RANTES, and fractalkine.11,24,25 Areas of focal necrosis with
inflammatory reactions have long been described in pulmo-
nary vessel walls of patients with primary PH. More recently,
perivascular inflammatory cell infiltrates have been found in
plexiform lesions. Given that some cytokines promote throm-
bosis and are considered potential mitogens, our results
demonstrating a link between IL-1 and 5-HTT also provide
new insight into the mechanisms by which inflammation may
contribute to vessel wall remodeling and in situ microthrom-
bosis in PH via stimulation of 5-HTT expression.
Stimulation of 5-HTT expression by inflammatory cyto-
kines may also account for the 5-HTT upregulation observed
in patients with PH, whether primary or associated with
various pulmonary or systemic diseases. Indeed, we previ-
ously reported that overexpression of 5-HTT in humans with
PH was only partly related to 5-HTT gene polymorphism.3,4
That inflammatory cytokines such as IL-1 and MCP-1
stimulate 5-HTT expression is an important finding, as it may
help us understand how environmental factors such as inflam-
mation contribute to 5-HTT overexpression and therefore to
the pathogenesis of pulmonary vascular remodeling. Recip-
rocally, the fact that 5-HTT blockade reverses PH and
simultaneously normalizes the late expression of these cyto-
kines supports the concept that altered 5-HTT expression is a
primary abnormality in the pathogenesis of PH and that
selective 5-HTT inhibition may represent a novel treatment
strategy directed against the pulmonary vascular remodeling
process that underlies all forms of human PH.
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